Medication-induced movement disorders: recognition and management

Medication-induced movement disorders (DIMD) are neurological adverse effects caused by medications that block dopamine receptors. They are among the most common iatrogenic neurological problems encountered in general practice, affecting approximately 37% of antipsychotic users in some form (Australian Prescriber). The GP’s role is to recognise the syndrome, identify the causative drug, adjust or substitute it in collaboration with the prescribing specialist, and escalate appropriately.

A. The five syndromes — onset, features, and management

Understanding the approximate time from starting the medication to onset is the fastest clinical shortcut to identifying which syndrome is present.

Acute dystonia (onset: hours to days)

Acute dystonia produces sudden, sustained, often painful muscle contractions causing abnormal postures. Classic presentations include oculogyric crisis (eyes deviated upward), torticollis (neck twisted to one side), opisthotonus (arching of the back), and — the most dangerous — laryngospasm with impaired airway. Young men and people receiving their first dose of a high-potency typical antipsychotic are most at risk.

Management: Intramuscular or intravenous benztropine 1–2 mg, or biperiden 2.5–5 mg, produces rapid resolution — typically within minutes (eTG). Laryngeal dystonia with airway compromise is a 000-level emergency. Reduce or switch the offending drug; if the causative drug must be continued, continue oral anticholinergic cover for one to two weeks.

Akathisia (onset: days to weeks)

Akathisia combines a distressing subjective sense of inner motor restlessness — an irresistible need to move — with objective fidgeting, pacing, and an inability to remain seated. It is frequently misidentified as worsening anxiety or psychotic agitation, leading to the catastrophic error of increasing the very drug that is causing it. Akathisia carries the highest suicide risk of all extrapyramidal side effects and must always be considered when a patient on any dopamine-blocking agent or SSRI reports restlessness (Australian Prescriber).

Assessment: The Barnes Akathisia Rating Scale (BARS) captures both the subjective and objective components, and is useful for serial monitoring.

Management: Reduce the dose or switch to a lower-D2-affinity agent (quetiapine or clozapine). Propranolol 10–40 mg three times daily is PBS-listed and is the most evidence-supported pharmacological add-on (AMH). Anticholinergics are less effective for akathisia than for dystonia or parkinsonism. Short-term low-dose benzodiazepines may be used cautiously with monitoring (SafeScript/RTPM applies). Counsel the patient about suicide risk and monitor closely.

Drug-induced parkinsonism (onset: weeks to months)

Drug-induced parkinsonism (DIP) presents with the classic parkinsonian triad — bradykinesia, rigidity, and tremor — typically affecting both sides simultaneously or symmetrically. This symmetry helps distinguish it from idiopathic Parkinson’s disease, which almost always begins asymmetrically (NPS MedicineWise). DIP affects approximately 20% of antipsychotic users. Older adults receiving metoclopramide post-operatively are particularly vulnerable.

Key distinction: In DIP, the dopamine transporter scan (DAT-SPECT, a specialist investigation) is normal because dopamine-producing neurons are structurally intact — they are pharmacologically blocked, not degenerating. In idiopathic Parkinson’s disease, the DAT-SPECT is abnormal.

Management: Reduce or substitute the causative medication. Benztropine 0.5–2 mg twice daily (PBS general) improves bradykinesia and rigidity in DIP; avoid in older adults where anticholinergic burden causes confusion. Levodopa does not work in DIP — the neurons are intact but blocked — and may worsen underlying psychiatric conditions. Most cases of DIP resolve within weeks to months of removing the causative drug, though a minority develop persistent parkinsonism suggesting an unmasked underlying neurodegenerative disorder.

Tardive syndromes (onset: months to years)

Tardive syndromes develop after sustained (typically at least three months’) exposure to dopamine-blocking agents and are thought to result from D2 receptor supersensitivity caused by prolonged blockade. The most common is tardive dyskinesia — involuntary, repetitive orobuccolingual movements (lip smacking, tongue protrusion, chewing) that may also affect the trunk, limbs, and respiratory muscles. Other tardive syndromes include tardive dystonia, tardive akathisia, and tardive tremor.

Tardive dyskinesia affects approximately 7% of antipsychotic users (Australian Prescriber). Risk factors include female sex, older age, affective disorder diagnosis, diabetes, and higher cumulative dopamine antagonist exposure. Crucially, tardive syndromes often persist even after the causative drug is stopped, and may paradoxically worsen transiently on dose reduction (withdrawal-emergent dyskinesia).

Critical warning: Anticholinergic drugs that help DIP worsen tardive dyskinesia and must be avoided in this syndrome. This is the most clinically significant management distinction between the movement disorder syndromes.

AIMS surveillance: The Abnormal Involuntary Movement Scale (AIMS) should be used every three to six months for all patients on long-term dopamine antagonists as standard preventive care. Early detection enables earlier intervention before movements become irreversible.

Management of tardive dyskinesia:

• Slow taper or substitution of the culprit medication; switching to clozapine is the only antipsychotic change with evidence to improve tardive dyskinesia (Australian Prescriber).
• VMAT2 inhibitors are the pharmacological class with the best trial evidence for tardive dyskinesia: tetrabenazine (Xenazine) is PBS Authority-listed in Australia for tardive dyskinesia and Huntington chorea. Deutetrabenazine and valbenazine are TGA-approved internationally and have superior tolerability profiles but are not yet PBS-listed in Australia, limiting access for most patients.
• Clonazepam and propranolol provide symptomatic relief. Botulinum toxin (PBS Authority for focal dystonia) is useful for localised tardive dystonia.
• Movement disorder neurologist input is recommended for all persistent or disabling tardive syndromes.

Neuroleptic malignant syndrome (onset: hours to days, any time)

Neuroleptic malignant syndrome (NMS) is rare but life-threatening. The tetrad is: high fever (often above 40°C), severe muscle rigidity (lead-pipe), altered mental state (confusion to coma), and autonomic instability (fluctuating blood pressure, tachycardia, diaphoresis, sialorrhoea). Serum CK is typically markedly elevated — above 1000 U/L — reflecting severe rhabdomyolysis that can cause acute kidney injury (StatPearls).

NMS is a medical emergency. Call 000, cease the offending drug immediately, and arrange Category 1 transfer to hospital. Supportive care in ICU includes intravenous fluid resuscitation, active cooling, and monitoring for renal failure. Specific treatments include bromocriptine (a dopamine agonist to counter D2 blockade) and dantrolene (a muscle relaxant to reduce rigidity and hyperthermia). Benzodiazepines manage agitation. Further D2-blocking agents should be avoided. Recovery takes weeks; rechallenge with any antipsychotic requires specialist guidance, using a different agent at a very low starting dose with very slow titration.

B. Evidence highlights

The most practically important evidence points for GP management:

Atypical antipsychotics preferred over typicals for first-episode psychosis on both DIMD and metabolic grounds when clinical evidence supports comparable efficacy (PMC 2018). The risk gradient runs: typical (haloperidol, chlorpromazine) > risperidone/paliperidone > olanzapine > quetiapine/clozapine.

Metoclopramide in older adults: TGA black-box warning restricts metoclopramide to no more than five days at standard doses in older adults due to tardive dyskinesia risk. Consider ondansetron as an alternative antiemetic in this population — it does not block D2 receptors and therefore does not cause DIMD.

AIMS screening is standard of care in all patients on long-term D2 antagonists. Documenting a baseline AIMS before starting an antipsychotic, and repeating it every three to six months, is recommended by Australian Prescriber and the Movement Disorders Society of Australia and New Zealand (MDSANZ).

Vitamin E for tardive dyskinesia: Cochrane reviews have found modest benefit in some studies but the effect size is small and high-dose supplementation carries cardiovascular risk. It is not a standard treatment but is sometimes used as an adjunct.

C. Australian operations — MBS, PBS, and safety systems

MBS consultations: GP standard, long, and prolonged consultations (items 23, 36, 44). GPCCMP for chronic disease management planning (items 965/967). Mental Health Care Plans where appropriate (items 2715/2717). ATSI health check (item 715). MRI brain where structural cause needs exclusion (item 63007).

PBS medications:

• Antipsychotics (typical and atypical) — PBS Authority Required; specialist-initiated in most cases.
• Tetrabenazine (Xenazine) — PBS Authority Required for tardive dyskinesia and Huntington chorea; prescribing restricted to neurologists and psychiatrists. This is currently the only VMAT2 inhibitor PBS-listed in Australia.
• Benztropine, benzhexol (trihexyphenidyl) — anticholinergics for acute dystonia and DIP, PBS General Schedule.
• Propranolol — PBS General Schedule for akathisia.
• Botulinum toxin — PBS Authority for focal dystonia in eligible patients.
• Bromocriptine, dantrolene — for NMS; supplied via hospital formularies.
• Clozapine — PBS Authority Required; mandatory REMS (Clozapine Patient Monitoring System) with regular absolute neutrophil count monitoring.

SafeScript / Real-Time Prescription Monitoring (RTPM): Applies in all Australian states and territories to benzodiazepines used for akathisia; check before prescribing.

TGA safety communications: The TGA black-box warning on metoclopramide in older adults and the black-box warning on antipsychotics regarding increased mortality in elderly patients with dementia-related psychosis are prescribing obligations, not optional guidance.

D. Special populations

Older adults are disproportionately affected by all DIMD, particularly DIP from antiemetics. Anticholinergic burden is especially problematic in this population — benztropine should be used with caution given the risk of confusion, urinary retention, and constipation in older patients. Metoclopramide and prochlorperazine should be avoided where possible; ondansetron is a safer antiemetic alternative. AIMS surveillance is especially important given the higher baseline risk.

Aboriginal and Torres Strait Islander patients: Coordinate with Aboriginal Community Controlled Health Organisations (ACCHOs) and specialist services. Closing the Gap PBS co-payment scheme applies. Cultural safety considerations are particularly relevant for patients with serious mental illness navigating complex medication regimens.

Children and adolescents are at higher risk of acute dystonia from antipsychotics than adults. Akathisia in this age group may present as behavioural disturbance or school refusal, making the diagnosis easily missed. Tardive dyskinesia can be permanent and is an important consideration before initiating long-term antipsychotics in young people.

Pregnancy: Most antipsychotics cross the placenta. DIP and tardive dyskinesia have been reported in neonates following in utero exposure. These decisions require joint GP, obstetric, and psychiatric management; the risks of untreated mental illness are generally balanced against medication risks on an individual basis.

People with dementia: Antipsychotics are used cautiously in this population given both the mortality black-box warning and the high DIMD risk. The lowest effective dose for the shortest necessary duration is the guiding principle; metoclopramide and prochlorperazine should be avoided entirely.

When to escalate

Seek emergency care (call 000) immediately for:

• High fever, severe rigidity, confusion, or profuse sweating after any change in antipsychotic dose — suspect neuroleptic malignant syndrome
• Laryngeal dystonia causing breathing difficulty

Contact your GP the same day for:

• New involuntary movements of the face, tongue, or limbs after starting or changing a medication
• Akathisia with distressing restlessness, particularly with any thoughts of self-harm
• Acute painful muscle spasm or abnormal neck or eye posture

Routine GP review within one to two weeks for:

• New tremor, stiffness, or slowing of movement after starting an antipsychotic or antiemetic
• Emerging tongue or mouth movements in a patient on long-term antipsychotics — urgent AIMS assessment and psychiatric review needed

Never stop antipsychotic medication abruptly without medical guidance — sudden withdrawal risks psychiatric relapse and may itself cause emergent dyskinesia (SANE Australia).

What this article is and is not

This article provides guideline-aligned educational information about medication-induced movement disorders for an Australian audience. It is not a substitute for clinical assessment by your GP, psychiatrist, or neurologist. Adjusting antipsychotic medication must always be done in consultation with your treating specialist given the risks of psychiatric relapse — medication changes described here reflect principles, not a licence for self-directed dose changes. If you are experiencing any of the symptoms described, please seek appropriate medical assessment rather than relying on this article alone.

---

Sources cited

1. Australian Prescriber — Drug-induced movement disorders
2. NPS MedicineWise — Drug-induced movement disorders PDF
3. Antipsychotic-Related Movement Disorders. PMC 2018
4. StatPearls — Extrapyramidal side effects
5. Movement Disorders Society of Australia and New Zealand (MDSANZ)
6. eTG complete — Drug-induced movement disorders
7. AMH — Australian Medicines Handbook
8. Pharmaceutical Benefits Scheme
9. HealthDirect — Antipsychotic medicines
10. SANE Australia — Antipsychotic medication side effects